[The modern view on the role of inflammatory factors in chronic heart failure and possibilities of pharmacological modification].
Chronic heart failure (CHF) is the state of reciprocal influences of neurohormonal factors and inflammatory markers. Many years of research and observations proved a particular meaning of cytokines and acute phase proteins in the pathophysiology of CHF. These markers are responsible for the repairing processes. There is a correlation between the activity of inflammatory factors, their plasma concentrations and clinical state of the patient. Basing on the cytokine's concentrations, the level of C-Reactive Protein (CRP) in the patient's blood and their changes in time we can predict the progression of the disease. Known medical references emphasise the fact that the pharmacological modification of inflammatory markers (interleukins, TNF-alfa, CRP) can have significant clinical consequences and in some cases can even cause regression of pathological symptoms. CRP plays an important role in the development and progression CHF and can be the clinical predictor not only in the cases of coronary disease but also can be useful in the group of patients with CHF. The introduction of drugs influencing CRP, interleukins and TNF-alfa levels to CHF therapy can be an effective solution called 'a golden therapy' improving clinical state and quality of patient's life.